144 related articles for article (PubMed ID: 7460402)
1. Pulmonary hypertension in systemic lupus erythematosus: hemodynamics and effects of vasodilator therapy.
Santini D; Fox D; Kloner RA; Konstam M; Rude RE; Lorell BH
Clin Cardiol; 1980 Dec; 3(6):406-11. PubMed ID: 7460402
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary hypertension in systemic lupus erythematosus.
Gladman DD; Sternberg L
J Rheumatol; 1985 Apr; 12(2):365-7. PubMed ID: 4032410
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary hypertension in systemic lupus erythematosus: effect of vasodilators on pulmonary hemodynamics.
Mahowald ML; Weir EK; Ridley DJ; Messner RP
J Rheumatol; 1985 Aug; 12(4):773-7. PubMed ID: 4057200
[TBL] [Abstract][Full Text] [Related]
4. Contrasting acute effects of vasodilators (nitroglycerin, nitroprusside, and hydralazine) on right ventricular performance in patients with chronic obstructive pulmonary disease and pulmonary hypertension: a combined radionuclide-hemodynamic study.
Brent BN; Berger HJ; Matthay RA; Mahler D; Pytlik L; Zaret BL
Am J Cardiol; 1983 Jun; 51(10):1682-9. PubMed ID: 6407295
[TBL] [Abstract][Full Text] [Related]
5. Detrimental effects of hydralazine in patients with chronic air-flow obstruction and pulmonary hypertension. A combined hemodynamic and radionuclide study.
Tuxen DV; Powles AC; Mathur PN; Pugsley SO; Campbell EJ
Am Rev Respir Dis; 1984 Mar; 129(3):388-95. PubMed ID: 6322627
[TBL] [Abstract][Full Text] [Related]
6. The effects of hydralazine on exercise capacity in pulmonary hypertension secondary to chronic obstructive pulmonary disease.
Dal Nogare AR; Rubin LJ
Am Rev Respir Dis; 1986 Mar; 133(3):385-9. PubMed ID: 3954247
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine.
Adnot S; Defouilloy C; Brun-Buisson C; Abrouk F; Piquet J; Lemaire F
Am Rev Respir Dis; 1987 Feb; 135(2):288-93. PubMed ID: 3813189
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill: another report.
Miller MH
Ann Rheum Dis; 1987 Feb; 46(2):159-61. PubMed ID: 3827339
[TBL] [Abstract][Full Text] [Related]
9. Disease activity is related to acute response to vasodilator in pulmonary artery hypertension associated with systemic lupus erythematosus.
Tian Z; Liu Y; Xu D; Li M; Lai J; Guo X; Wang H; Zhu W; Wang Q; Fang Q; Zeng X
Circ J; 2014; 78(5):1240-4. PubMed ID: 24562636
[TBL] [Abstract][Full Text] [Related]
10. Severe pulmonary hypertension in a patient with systemic lupus erythematosus and minimal lupus activity.
Kawamura N; Tsutsui H; Fukuyama K; Hayashidani S; Koike G; Egashira K; Abe Y; Yamamoto H; Tsuneyoshi M; Takeshita A
Intern Med; 2002 Feb; 41(2):109-12. PubMed ID: 11868596
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary hypertension in infants with bronchopulmonary dysplasia.
Goodman G; Perkin RM; Anas NG; Sperling DR; Hicks DA; Rowen M
J Pediatr; 1988 Jan; 112(1):67-72. PubMed ID: 3335964
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of vasodilators on pulmonary hypertension in decompensated chronic obstructive pulmonary disease.
Cerdá E; Esteban A; de la Cal MA; Fernández A; García A
Crit Care Med; 1985 Apr; 13(4):221-3. PubMed ID: 3979067
[TBL] [Abstract][Full Text] [Related]
13. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.
Robbins IM; Gaine SP; Schilz R; Tapson VF; Rubin LJ; Loyd JE
Chest; 2000 Jan; 117(1):14-8. PubMed ID: 10631192
[TBL] [Abstract][Full Text] [Related]
14. Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension.
McGoon MD; Seward JB; Vlietstra RE; Choo MH; Moyer TP; Reeder GS
Br Heart J; 1983 Dec; 50(6):579-85. PubMed ID: 6652000
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of vasodilator therapy for pulmonary arterial hypertension.
Rubin LJ
Clin Chest Med; 1983 May; 4(2):309-19. PubMed ID: 6342925
[No Abstract] [Full Text] [Related]
16. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis.
Menon N; McAlpine L; Peacock AJ; Madhok R
Arthritis Rheum; 1998 Mar; 41(3):466-9. PubMed ID: 9506575
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost.
Mok MY; Tse HF; Lau CS
Lupus; 1999; 8(4):328-31. PubMed ID: 10413214
[TBL] [Abstract][Full Text] [Related]
18. Systemic lupus erythematosus-associated pulmonary hypertension: good outcome following sildenafil therapy.
Molina J; Lucero E; Luluaga S; Bellomio V; Spindler A; Berman A
Lupus; 2003; 12(4):321-3. PubMed ID: 12729058
[TBL] [Abstract][Full Text] [Related]
19. Oral hydralazine therapy for primary pulmonary hypertension.
Rubin LJ; Peter RH
N Engl J Med; 1980 Jan; 302(2):69-73. PubMed ID: 7350435
[TBL] [Abstract][Full Text] [Related]
20. Could pulmonary arterial hypertension be an active index of systemic lupus erythematosus? A successful case of SLE-PAH cured by methylprednisolone pulse therapy.
Huang C; Zhang S; Tian Z; Li M; Zeng X
Lupus; 2014 Dec; 23(14):1533-6. PubMed ID: 25260565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
